Full Text View
Tabular View
No Study Results Posted
Related Studies
Depodur vs Fentanyl Infusion for Post-C/S Analgesia
This study is not yet open for participant recruitment.
Verified by Goodman, Evan, M.D., September 2008
First Received: September 29, 2008   No Changes Posted
Sponsor: Goodman, Evan, M.D.
Information provided by: Goodman, Evan, M.D.
ClinicalTrials.gov Identifier: NCT00762554
  Purpose

Epidurally administered Depodur provides equal or superior analgesia as an epidural infusion of fentanyl for the first 48 hours after a cesarean section.


Condition Intervention
Analgesia
Drug: Depodur
Drug: Fentanyl

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Outcomes Assessor), Uncontrolled, Parallel Assignment, Efficacy Study
Official Title: A Comparison of Single Dose Depodur With Fentanyl Infusion for Post-Cesarean Section Analgesia

Resource links provided by NLM:


Further study details as provided by Goodman, Evan, M.D.:

Primary Outcome Measures:
  • Degree of analgesia (measured on a 10-point scale) [ Time Frame: 48 hours post-operatively ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Frequency of minor side effects, such as pruritis or nausea. [ Time Frame: 48 hours postoperatively ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: October 2008
Estimated Study Completion Date: June 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
Epidural Depodur after epidural lidocaine
Drug: Depodur
Depodur 10mg given epidurally at end of cesarean section.
2: Active Comparator
Epidural Depodur after spinal bupivacaine
Drug: Depodur
Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
3: Active Comparator
Epidural fentanyl infusion after epidural lidocaine or spinal bupivacaine
Drug: Fentanyl
Epidural fentanyl infusion started after epidural lidocaine or spinal bupivacaine used for the cesarean section.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy pregnant women (ASA I or II) who are scheduled for an elective cesarean section
  • Patient appropriate for regional anesthesia
  • Patient agrees to receive regional anesthesia
  • Patient willing to have an epidural infusion of medication for two days postoperatively

Exclusion Criteria:

  • Morbid obesity
  • History of sleep apnea
  • Allergy to opioids medications
  • History of opioids use during week prior to procedure
  • Emergency cesarean section
  • Significant surgical complications
  • Contraindication or refusal to have regional anesthesia
  • Age less than 18
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00762554

Locations
United States, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
Goodman, Evan, M.D.
  More Information

Publications:
Responsible Party: University Hospitals Case Medical Center ( Evan Goodman, MD )
Study ID Numbers: goodman-1
Study First Received: September 29, 2008
Last Updated: September 29, 2008
ClinicalTrials.gov Identifier: NCT00762554     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Goodman, Evan, M.D.:
analgesia
cesarean section
fentanyl
Depodur
Post-cesarean section analgesia

Additional relevant MeSH terms:
Anesthetics, Intravenous
Morphine
Fentanyl
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Adjuvants, Anesthesia
Anesthetics, General
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on February 08, 2010